| Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole A Rossello, S Bertini, A Lapucci, M Macchia, A Martinelli, S Rapposelli, ... Journal of Medicinal Chemistry 45 (22), 4903-4912, 2002 | 181 | 2002 |
| The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells O Rosso, T Piazza, I Bongarzone, A Rossello, D Mezzanzanica, ... Molecular Cancer Research 5 (12), 1246-1253, 2007 | 143 | 2007 |
| Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors E Nuti, T Tuccinardi, A Rossello Current pharmaceutical design 13 (20), 2087-2100, 2007 | 140 | 2007 |
| Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies M Bozdag, M Ferraroni, E Nuti, D Vullo, A Rossello, F Carta, A Scozzafava, ... Bioorganic & Medicinal Chemistry 22 (1), 334-340, 2014 | 116 | 2014 |
| New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) A Rossello, E Nuti, E Orlandini, P Carelli, S Rapposelli, M Macchia, ... Bioorganic & medicinal chemistry 12 (9), 2441-2450, 2004 | 102 | 2004 |
| Strategies to target ADAM17 in disease: from its discovery to the iRhom revolution M Calligaris, D Cuffaro, S Bonelli, DP Spanò, A Rossello, E Nuti, ... Molecules 26 (4), 944, 2021 | 100 | 2021 |
| Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)-and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3 … T Tuccinardi, A Martinelli, E Nuti, P Carelli, F Balzano, G Uccello-Barretta, ... Bioorganic & medicinal chemistry 14 (12), 4260-4276, 2006 | 98 | 2006 |
| Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II T Takayanagi, SJ Forrester, T Kawai, T Obama, T Tsuji, KJ Elliott, E Nuti, ... Hypertension 68 (4), 949-955, 2016 | 83 | 2016 |
| N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential … E Nuti, F Casalini, SI Avramova, S Santamaria, G Cercignani, L Marinelli, ... Journal of medicinal chemistry 52 (15), 4757-4773, 2009 | 83 | 2009 |
| New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties MC Breschi, V Calderone, M Digiacomo, M Macchia, A Martelli, ... Journal of medicinal chemistry 49 (8), 2628-2639, 2006 | 83 | 2006 |
| N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity E Nuti, AR Cantelmo, C Gallo, A Bruno, B Bassani, C Camodeca, ... Journal of Medicinal Chemistry 58 (18), 7224-7240, 2015 | 79 | 2015 |
| Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma P Gabelloni, E Da Pozzo, S Bendinelli, B Costa, E Nuti, F Casalini, ... Neuroscience 168 (2), 514-522, 2010 | 76 | 2010 |
| Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors E Nuti, L Panelli, F Casalini, SI Avramova, E Orlandini, S Santamaria, ... Journal of medicinal chemistry 52 (20), 6347-6361, 2009 | 72 | 2009 |
| Crystallization of bi-functional ligand protein complexes C Antoni, L Vera, L Devel, MP Catalani, B Czarny, E Cassar-Lajeunesse, ... Journal of Structural Biology 182 (3), 246-254, 2013 | 67 | 2013 |
| Deficient natural killer cell NKp30‐mediated function and altered NCR3 splice variants in hepatocellular carcinoma S Mantovani, B Oliviero, A Lombardi, S Varchetta, D Mele, A Sangiovanni, ... Hepatology 69 (3), 1165-1179, 2019 | 66 | 2019 |
| Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate− benzenesulfonamide conjugates SM Marques, E Nuti, A Rossello, CT Supuran, T Tuccinardi, A Martinelli, ... Journal of medicinal chemistry 51 (24), 7968-7979, 2008 | 64 | 2008 |
| Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates E Nuti, E Orlandini, S Nencetti, A Rossello, A Innocenti, A Scozzafava, ... Bioorganic & medicinal chemistry 15 (6), 2298-2311, 2007 | 62 | 2007 |
| α-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs A Biasone, P Tortorella, C Campestre, M Agamennone, S Preziuso, ... Bioorganic & medicinal chemistry 15 (2), 791-799, 2007 | 62 | 2007 |
| Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups M Bozdag, M Ferraroni, F Carta, D Vullo, L Lucarini, E Orlandini, ... Journal of Medicinal Chemistry 57 (21), 9152-9167, 2014 | 61 | 2014 |
| Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors MA Santos, SM Marques, T Tuccinardi, P Carelli, L Panelli, A Rossello Bioorganic & medicinal chemistry 14 (22), 7539-7550, 2006 | 61 | 2006 |
Elisabetta Orlandiniassociate professor medicinal chemistry Pisa UniversityПотвърден имейл адрес: unipi.it
